Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : Agenda

share with twitter share with LinkedIn share with facebook
09/18/2020 | 09:48am EDT

Agenda CMD

September 16, 2020

10:00-

Presentation

10:30

Group

CEO/CFO

10:30-

Sector Intros + Q&A

12:00

Executive Board

12:45-

Presentation + Q&A

13:45

Life Science:

Process Solutions

14:00-

Presentation + Q&A

15:00

Performance Materials:

Semiconductor Solutions

09/25/20

Presentation + Q&A

Healthcare:

R&D Update

09/16/20 1st ViRtual CMD

At Merck

KGaA,

Darmstadt,

This virtual Capital Markets Day

Germany,

we

have

been

will also offer you the opportunity

successfully

moving

with

the

to discuss with the Executive

times for over 350 years. We are

Board, including our sector CEOs.

on a journey of transformation,

In addition, we will hold in-

and the current crisis is no

exception.

depth sessions on two of our

most important

growth drivers:

With that said, we are excited to

Process

Solutions

and

cordially invite you to attend our

Semiconductor Solutions. To stay

first virtual Capital Markets Day

within a reasonable time frame, a

(CMD) event for investors and

deep dive into Healthcare R&D

analysts. It will be held on

will follow during a separate

Wednesday,

September

16,

conference call on September 25,

2020 from 10:00 a.m. until 3:00

2020 (invitation to follow soon).

p.m. (CEST).

You can look forward to

Group CEO

Stefan

Oschmann

insightful

presentations and

the

and CFO Marcus Kuhnert will

opportunity to

address

your

provide an overview of the latest

questions to the specialists at

developments and future plans to

Merck

KGaA,

Darmstadt,

continue the

Company success

Germany.

story and journey of profitable growth.

We look forward to your participation!

There will be a live webcast of the entire event.

The recorded webcast will be available as of the next day.

The link will be published prior to the event on our homepage.

Disclaimer

Merck KGaA published this content on 11 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 September 2020 12:14:07 UTC


share with twitter share with LinkedIn share with facebook
All news about MERCK KGAA
10/30MERCK KGAA : Sell rating from Goldman Sachs
MD
10/29MERCK : Mammoth Biosciences Partner to Produce, Scale Up Covid-19 Test
DJ
10/28MERCK KGAA : Kepler Cheuvreux remains its Buy rating
MD
10/28MERCK : to Invest EUR20 Million in Display-Technology Production
DJ
10/27MERCK : MAVENCLAD® (cladribine tablets) is available through public drug plans f..
AQ
10/27MERCK KGAA : JP Morgan remains Neutral
MD
10/21MERCK KGAA : Morgan Stanley reaffirms its Neutral rating
MD
10/21MERCK KGAA : Bernstein reiterates its Neutral rating
MD
10/16Physiomics Wins Contracts With Existing Customers
DJ
10/15MERCK : Global Head of R&D for Healthcare to Retire
DJ
More news
Financials
Sales 2020 17 300 M 20 146 M 20 146 M
Net income 2020 1 724 M 2 008 M 2 008 M
Net Debt 2020 10 781 M 12 554 M 12 554 M
P/E ratio 2020 30,5x
Yield 2020 1,07%
Capitalization 55 282 M 64 424 M 64 376 M
EV / Sales 2020 3,82x
EV / Sales 2021 3,53x
Nbr of Employees 57 523
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 126,95 €
Last Close Price 127,15 €
Spread / Highest target 18,0%
Spread / Average Target -0,15%
Spread / Lowest Target -20,6%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Independent Member-Supervisory Board
Edeltraud Glänzer Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA20.69%64 424
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD108.70%20 679
KYOWA KIRIN CO., LTD.0.66%13 303
BETTA PHARMACEUTICALS CO., LTD.62.97%6 450
YUHAN CORPORATION25.79%3 282
RECIPHARM AB (PUBL)9.32%1 627